These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31335138)

  • 1. Discovery and Development of a Series of Pyrazolo[3,4-
    Wang Y; Dai Y; Wu X; Li F; Liu B; Li C; Liu Q; Zhou Y; Wang B; Zhu M; Cui R; Tan X; Xiong Z; Liu J; Tan M; Xu Y; Geng M; Jiang H; Liu H; Ai J; Zheng M
    J Med Chem; 2019 Aug; 62(16):7473-7488. PubMed ID: 31335138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Based Discovery of a Series of 5H-Pyrrolo[2,3-b]pyrazine FGFR Kinase Inhibitors.
    Jiang A; Liu Q; Wang R; Wei P; Dai Y; Wang X; Xu Y; Ma Y; Ai J; Shen J; Ding J; Xiong B
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29562726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and Biological Evaluation of a Series of Pyrrolo[2,3-b]pyrazines as Novel FGFR Inhibitors.
    Zhang Y; Liu H; Zhang Z; Wang R; Liu T; Wang C; Ma Y; Ai J; Zhao D; Shen J; Xiong B
    Molecules; 2017 Apr; 22(4):. PubMed ID: 28379191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer molecules targeting fibroblast growth factor receptors.
    Liang G; Liu Z; Wu J; Cai Y; Li X
    Trends Pharmacol Sci; 2012 Oct; 33(10):531-41. PubMed ID: 22884522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide and Its Analogs Differentially Target Fibroblast Growth Factor Receptors: Thalidomide Suppresses FGFR Gene Expression while Pomalidomide Dampens FGFR2 Activity.
    Sundaresan L; Kumar P; Manivannan J; Balaguru UM; Kasiviswanathan D; Veeriah V; Anishetty S; Chatterjee S
    Chem Res Toxicol; 2019 Apr; 32(4):589-602. PubMed ID: 30834740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments and advances of FGFR as a potential target in cancer.
    Xue WJ; Li MT; Chen L; Sun LP; Li YY
    Future Med Chem; 2018 Sep; 10(17):2109-2126. PubMed ID: 30066580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors.
    Fan J; Dai Y; Shao J; Peng X; Wang C; Cao S; Zhao B; Ai J; Geng M; Duan W
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2594-9. PubMed ID: 27117427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis and Biological Evaluation of 6-(2,6-Dichloro-3,5-dimethoxyphenyl)-4-substituted-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors.
    Zhang Z; Zhao D; Dai Y; Cheng M; Geng M; Shen J; Ma Y; Ai J; Xiong B
    Molecules; 2016 Oct; 21(10):. PubMed ID: 27782099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGFR-TKI resistance in cancer: current status and perspectives.
    Yue S; Li Y; Chen X; Wang J; Li M; Chen Y; Wu D
    J Hematol Oncol; 2021 Feb; 14(1):23. PubMed ID: 33568192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models.
    Squires M; Ward G; Saxty G; Berdini V; Cleasby A; King P; Angibaud P; Perera T; Fazal L; Ross D; Jones CG; Madin A; Benning RK; Vickerstaffe E; O'Brien A; Frederickson M; Reader M; Hamlett C; Batey MA; Rich S; Carr M; Miller D; Feltell R; Thiru A; Bethell S; Devine LA; Graham BL; Pike A; Cosme J; Lewis EJ; Freyne E; Lyons J; Irving J; Murray C; Newell DR; Thompson NT
    Mol Cancer Ther; 2011 Sep; 10(9):1542-52. PubMed ID: 21764904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advance in the development of novel, selective and potent FGFR inhibitors.
    Liu FT; Li NG; Zhang YM; Xie WC; Yang SP; Lu T; Shi ZH
    Eur J Med Chem; 2020 Jan; 186():111884. PubMed ID: 31761386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Characterization of the Interaction of the Fibroblast Growth Factor Receptor with a Small Molecule Allosteric Inhibitor.
    Kappert F; Sreeramulu S; Jonker HRA; Richter C; Rogov VV; Proschak E; Hargittay B; Saxena K; Schwalbe H
    Chemistry; 2018 Jun; 24(31):7861-7865. PubMed ID: 29656465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting mutant fibroblast growth factor receptors in cancer.
    Greulich H; Pollock PM
    Trends Mol Med; 2011 May; 17(5):283-92. PubMed ID: 21367659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and characteristics of cytotoxic fibroblast growth factor 1 conjugate for fibroblast growth factor receptor-targeted cancer therapy.
    Szlachcic A; Zakrzewska M; Lobocki M; Jakimowicz P; Otlewski J
    Drug Des Devel Ther; 2016; 10():2547-60. PubMed ID: 27563235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors.
    Liu Y; Peng X; Guan X; Lu D; Xi Y; Jin S; Chen H; Zeng L; Ai J; Geng M; Hu Y
    Eur J Med Chem; 2017 Jan; 126():122-132. PubMed ID: 27750146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffold.
    Liu J; Peng X; Dai Y; Zhang W; Ren S; Ai J; Geng M; Li Y
    Org Biomol Chem; 2015 Jul; 13(28):7643-54. PubMed ID: 26080733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances of dual FGFR inhibitors as a novel therapy for cancer.
    Liang Q; Wang J; Zhao L; Hou J; Hu Y; Shi J
    Eur J Med Chem; 2021 Mar; 214():113205. PubMed ID: 33556787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention.
    De Luca A; Esposito Abate R; Rachiglio AM; Maiello MR; Esposito C; Schettino C; Izzo F; Nasti G; Normanno N
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor receptor inhibitors: patent review (2015-2019).
    Marseglia G; Lodola A; Mor M; Castelli R
    Expert Opin Ther Pat; 2019 Dec; 29(12):965-977. PubMed ID: 31679402
    [No Abstract]   [Full Text] [Related]  

  • 20. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.
    Hierro C; Rodon J; Tabernero J
    Semin Oncol; 2015 Dec; 42(6):801-19. PubMed ID: 26615127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.